Skip to main content
Caplight Logo









Coherent Biopharma

Coherent Biopharma

Private
SuzhouHealthcare & Life Scienceshttp://www.coherentbiopharma.com/

Last Round

Series B

May 23, 2023

Total Funding Raised

$128M

Company Overview

Coherent Biopharma is a clinical-stage biopharmaceutical company that develops bispecific-targeting ligand drug conjugates (Bi-XDC) for the treatment of cancer and other chronic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Application

Keywords

Bi-XDC platformBi-specific, Bi-ligand Drug Conjugatestargeted cancer therapyclinical stage biopharmaoncology drug candidatessmall molecule drug conjugateprecision oncologyC-PROTAC platformbiopharma licensingtargeted protein degradationsolid tumor therapydrug delivery platformAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Coherent Biopharma Comparables

Compare Coherent Biopharma with similar companies based on industry and business-model similarity.

Coherent Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cybrexa Therapeutics
82%
Bicycle Therapeutics
81%
Canwell Biotech Ltd.
77%

Coherent Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 23, 2023
Series A ExtensionOct 10, 2018

Coherent Biopharma Investors

Notable investors and investment history

Coherent Biopharma investors
InvestorRounds
Agricultural Bank of China InternationalSeries B
Hefei Industry Investment GroupSeries B
6 Dimensions CapitalSeries A Extension
Hefei Hi-Tech VCSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 23, 2023

    $100M round with Agricultural Bank of China International and Hefei Hi-Tech VC.

  • Oct 10, 2018

    $20M round led by 6 Dimensions Capital

Coherent Biopharma Filings

Explore SEC and related filing metadata, where available.

Coherent Biopharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Coherent Biopharma's valuation, stock price, and market status.

Is Coherent Biopharma a public or private company?

Coherent Biopharma is a private company.

What is the current stock price of Coherent Biopharma?

Coherent Biopharma is a private company, so its shares have no public market price. Caplight tracks Coherent Biopharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Coherent Biopharma worth (valuation)?

Valuation information for Coherent Biopharma is not publicly available.

Can I buy Coherent Biopharma stock?

Coherent Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Coherent Biopharma's last funding round?

Coherent Biopharma's most recent funding round was Series B on May 23, 2023.

Who are the main investors in Coherent Biopharma?

Key investors in Coherent Biopharma include 6 Dimensions Capital.

Will Coherent Biopharma IPO soon?

No public IPO plans have been announced for Coherent Biopharma.

How can I track Coherent Biopharma secondary market activity?

Caplight tracks bids, offers, and trades in Coherent Biopharma's shares on secondary markets.

Firmographic Details

HeadquartersSuzhou
Year Founded2016
Last FundingMay 23, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?